NASDAQ: CASI | 中文 | Contact Us

CASI News

CASI Pharmaceuticals And Bioinvent Announce CTA Approval For Clinical Study Of BI-1206 In NHL In China

December 10, 2021

CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announces that the China National Medical Products Administration (NMPA) has approved the Company’s Clinical Trial Application (CTA) for BI-1206, a First-in-class fully human monoclonal antibody (“mAb”) that targets FcγRIIB.

Read the press release.


CASI Pharmaceuticals Announces Dosing Of First Patient Of CID-103 In Phase 1 Clinical Trial For Relapsed Or Refractory Multiple Myeloma

June 10, 2021

CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced First-Patient-In in the Phase 1 dose escalation and expansion study of CID-103, an investigational novel anti-CD38 monoclonal antibody, in patients with previously treated, relapsed or refractory multiple myeloma. The study is designed to assess the safety, tolerability, pharmacology and clinical activity of CID-103.

Read the press release.


U.S. FDA-Approved Product

Evomela®

Multiple Myeloma

Clinical Candidates

CNTC19

Hematological Malignancies

BI-1206

Non-Hodgkin's Lymphoma and Solid Tumors

CB-5339

AML, MDS and Solid Tumors

CID-103

Multiple Myeloma
Learn more about our product pipeline

About Us

CASI is a U.S. NASDAQ-listed biopharmaceutical company with a platform to develop and accelerate the launch of pharmaceutical products and innovative therapeutics in China, the U.S., and throughout the world. We have offices in Rockville, Maryland, and a wholly owned subsidiary in Beijing, China, through which substantially all of our operations are conducted.

Learn More